Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-4-29
pubmed:abstractText
In the azoxymethane (AOM) model of experimental rodent colon cancer, cholic acid and its colonic metabolite deoxycholic acid (DCA) strongly promote tumorigenesis. In contrast, we showed that ursodeoxycholic acid (UDCA), a low abundance bile acid, inhibited AOM tumorigenesis. Dietary UDCA also blocked the development of tumors with activated Ras and suppressed cyclooxygenase-2 (Cox-2) upregulation in AOM tumors. In this study, we compared the effect of dietary supplementation with tumor-promoting cholic acid to chemopreventive UDCA on Cox-2 expression in AOM tumors. Cholic acid enhanced Cox-2 upregulation in AOM tumors, whereas UDCA inhibited this increase and concomitantly decreased CCAAT/enhancer binding protein beta (C/EBPbeta), a transcriptional regulator of Cox-2. In HCA-7 colon cancer cells, DCA activated Ras and increased C/EBPbeta and Cox-2 by a mechanism requiring the mitogen-activated protein kinase p38. UDCA inhibited DCA-induced p38 activation and decreased C/EBPbeta and Cox-2 upregulation. Using transient transfections, UDCA inhibited Cox-2 promoter and C/EBP reporter activation by DCA. Transfection with dominant-negative (17)N-Ras abolished DCA-induced p38 activation and C/EBPbeta and Cox-2 upregulation. Taken together, these studies have identified a transcriptional pathway regulating Cox-2 expression involving Ras, p38, and C/EBPbeta that is inhibited by UDCA. These signal transducers are novel targets of UDCA's chemopreventive actions.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0163-5581
pubmed:author
pubmed:issnType
Print
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
389-400
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:18444174-Animals, pubmed-meshheading:18444174-Azoxymethane, pubmed-meshheading:18444174-CCAAT-Enhancer-Binding Protein-beta, pubmed-meshheading:18444174-Cells, Cultured, pubmed-meshheading:18444174-Chemoprevention, pubmed-meshheading:18444174-Cholic Acid, pubmed-meshheading:18444174-Colonic Neoplasms, pubmed-meshheading:18444174-Cyclooxygenase 2, pubmed-meshheading:18444174-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:18444174-Dietary Supplements, pubmed-meshheading:18444174-Gene Expression Regulation, Neoplastic, pubmed-meshheading:18444174-Genes, ras, pubmed-meshheading:18444174-Signal Transduction, pubmed-meshheading:18444174-Transcription Factors, pubmed-meshheading:18444174-Transfection, pubmed-meshheading:18444174-Ursodeoxycholic Acid, pubmed-meshheading:18444174-p38 Mitogen-Activated Protein Kinases
pubmed:year
2008
pubmed:articleTitle
Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.
pubmed:affiliation
Department of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA. skhare@lumc.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural